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pre-clinical evaluation of a 
quadrivalent HCV VLp vaccine in 
pigs following microneedle delivery
D. Christiansen1, L. earnest-silveira1, B. Grubor-Bauk2, D. K. Wijesundara2, I. Boo3, 
p. A. Ramsland  3,4,5,6, e. Vincan7, H. e. Drummer3,8, e. J. Gowans2 & J. torresi1
The introduction of directly acting antiviral agents (DAAs) has produced significant improvements 
in the ability to cure chronic hepatitis C infection. However, with over 2% of the world’s population 
infected with HCV, complications arising from the development of cirrhosis of the liver, chronic hepatitis 
C infection remains the leading indication for liver transplantation. several modelling studies have 
indicated that DAAs alone will not be sufficient to eliminate HCV, but if combined with an effective 
vaccine this regimen would provide a significant advance towards achieving this critical World Health 
Organisation goal. We have previously generated a genotype 1a, 1b, 2a, 3a HCV virus like particle (VLP) 
quadrivalent vaccine. The HCV VLPs contain the core and envelope proteins (E1 and E2) of HCV and the 
vaccine has been shown to produce broad humoral and t cell immune responses following vaccination 
of mice. In this report we further advanced this work by investigating vaccine responses in a large 
animal model. We demonstrate that intradermal microneedle vaccination of pigs with our quadrivalent 
HCV VLP based vaccine produces long-lived multi-genotype specific and neutralizing antibody (NAb) 
responses together with strong T cell and granzyme B responses and normal Th1 and Th2 cytokine 
responses. these responses were achieved without the addition of adjuvant. our study demonstrates 
that our vaccine is able to produce broad immune responses in a large animal that, next to primates, 
is the closest animal model to humans. our results are important as they show that the vaccine can 
produce robust immune responses in a large animal model before progressing the vaccine to human 
trials.
Hepatitis C Virus (HCV) infects 2% of the world’s population and complications arising from chronic HCV 
remain the most common indication for liver transplantation. The advent of directly acting antiviral agents 
(DAAs) for chronic HCV has resulted in high cure rates for patients infected with all genotypes of HCV. However, 
re-infection remains an important problem, especially in individuals at high-risk for HCV infection1. In 2015 
there were an estimated 1.75 million new HCV infections and 71 million living with HCV worldwide2 and trans-
mission of HCV in several countries, like the United States, continues to rise3–6. Between 2014 and 2015 the num-
ber of reported cases of HCV in the US rose by 11%6. In Europe a similar pattern has emerged where the number 
of reported cases increased by 26% between 2006 and 20157. In Australia the overall notification rate for HCV has 
remained unchanged in the past 5 years but the annual incidence of hepatitis C among people who inject drugs 
(PWID) tripled between 2014 and 20158. In 2016 the number of cases of chronic hepatitis C (CHC) increased 
by 12% increase compared to 20159. The overriding message from these data is that even with broader access to 
DAAs, a combination of approaches including multifaceted preventative risk-reduction strategies and ultimately 
an effective vaccine together with DAAs will be required to achieve the elimination of HCV3.
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Although past resolved infection of HCV does not necessarily protect against reinfection, we know that clear-
ance of HCV after reinfection is twice as likely compared to individuals who become infected for the first time. 
The rapid induction of cross neutralizing antibody (NAb) is also associated with viral clearance in these individ-
uals1,10,11. These studies show that infected individuals develop protective immunity and so it should be possible 
to develop a vaccine that is able to prevent persistent infection.
Several HCV vaccine candidates have been studied to date. These have included recombinant proteins12,13, 
recombinant adenoviral and modified vaccinia Ankara (MVA), DNA and VLP vaccines in various prime boost 
approaches14–19 all with varying levels of success in producing potentially protective immune responses. To over-
come the diversity of HCV an effective vaccine must be capable of generating both broad and cross-reactive NAb 
plus cell mediated immune (CMI) responses across multiple HCV genotypes circulating in nature20,21.
Although development of NAb is associated with protection against HCV, the importance of CD4+ and CD8+ 
T cells in both the clearance of and protection against HCV cannot be understated22–24. The core protein of HCV 
is one of the most important targets of protective CMI responses against HCV and its inclusion in any vaccine 
would therefore be highly desirable22,24.
A number of HCV VLP based vaccines producing HCV specific humoral and CMI responses have been 
described13,18,25–31. These vaccines have been shown to produce cross reactive NAb and T cell responses in various 
animal modes including mice and macaques and partial protection in chimpanzees32,33.
We have produced an HCV virus like particle (VLP) vaccine containing the HCV core and the E1 and E2 
envelope glycoproteins and showed this vaccine induced NAb and T cell responses from a single vaccine con-
struct18,27,34,35. We have also produced a quadrivalent HCV VLP vaccine containing particles of genotypes 1a, 1b, 
2a and 3a34 and have shown that our vaccine produces strong antibody and T cell responses in mice35,36. Here we 
advance this work further by demonstrating that our quadrivalent vaccine produces robust immune responses 
in a pre-clinical large animal model that is of more relevance to human vaccination. Intradermal vaccination 
of Landrace pigs with quadrivalent VLP using a microneedle injector generated durable HCV multi-genotypic 
neutralizing antibody and CMI responses.
Results
Durable HCV VLP specific antibody responses following intradermal vaccination. We have pre-
viously shown that both genotype 1a25,34,35 and 3a18 HCV VLP vaccines produced strong antibody responses in 
mice. To broaden the immunogenicity of the vaccine we subsequently produced a quadrivalent genotype 1a, 1b, 
2a and 3a HCV VLP vaccine27 and demonstrated genotype specific immune responses in mice36. We have now 
advanced this work by testing the immunogenicity of our quadrivalent vaccine in a pre-clinical large animal 
model. Pigs were immunised 3 times, 21 days apart by intradermal or intramuscular injection and followed out 
to day 84-post inoculation (Fig. 1). These two routes of inoculation were selected as they represent two common 
routes of vaccine administration in humans. Sera collected at each time point were tested by ELISA to determine 
antibody responses (Fig. 2). Pigs in both groups developed an early antibody response at day 21. The responses 
peaked in both groups at day 56 and persisted to day 84, the last collection time point. Importantly, antibody 
responses were significantly higher at all time points tested in pigs vaccinated by the intradermal route when 
compared to intramuscular (Fig. 2).
As the intradermal group had superior antibody responses at all time points for the duration of the experi-
ment, antibody responses were further characterised only in this group of pigs. Antibody responses were analysed 
for each collection time point for each of the individual pigs by ELISA (Fig. 3A–E). Lower absorbance values 
were observed from each of the individual pigs at d21 (Fig. 3A). The geometric mean titre (GMT) at day 21 was 
3.18 log10 (95%CI 2.65 to 3.72). After d21 and the third dose of vaccine antibody titres increased significantly 
(Fig. 3B–E), reaching a peak for all pigs between d42 (GMT 3.74 log10 [95%CI 3.27 to 4.34] p = 0.03) and d56 
(GMT 3.58 log10 [95%CI 3.12 to 4.11], p < 0.05) (Fig. 3B,C,F). Thereafter titres remained high at day 70 Fig. 3D 
(GMT 3.56 log10 95%CI 3.14 to 4.04, p = 0.045) and persisted through to the completion of the experiment at day 
84 (Fig. 3E) (GMT (3.43 log10, 95%CI 2.69 to 4.36, p = 0.14)(Fig. 3F). Throughout the duration of the experiment 
antibody responses were typically highest for pig 12 compared to pigs 10 and 11.
Figure 1. Overview of the HCV VLP quadrivalent vaccine immunisation, bleeding and testing schedule. Two 
groups of 3 pigs were immunized with 3 doses 21 days apart of quadrivalent vaccine by intradermal (Group 1) 
or intramuscular (Group 2) vaccination. Each dose consisted of a total of 300 µg of HCV VLP, containing 75 µg 
of each genotype. The assays performed at each sampling point are shown.
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We next determined the ability of the vaccine to induce the production of IgG1 and 2 subclasses as both have 
been shown to play important roles in protective humoral immune responses against viral infections37–41. We 
focused the analysis on the group inoculated by the intradermal route as this group produced the highest anti-
body titres. Both IgG1 and IgG2 were detected as early as day 21 after the first dose of the quadrivalent vaccine 
and they continued to significantly increase with each booster dose, peaking by day 56 and persisting to day 84 
(Fig. 4).
HCV genotype specific antibody responses following intradermal vaccination. We recently 
showed that our quadrivalent vaccine produced HCV genotype-specific antibody responses in mice36. Therefore, 
it was important to demonstrate that the same responses were possible in a pre-clinical large animal model. 
Furthermore, we also wanted to determine the long-term durability of the genotype specific response.
Background antibody levels against each of the HCV genotypes were detected in pre-bleed sera on day 0 
(Fig. 5, d0), however genotype specific antibody levels significantly increased following immunisation and were 
detected after a single vaccine dose (d21)(Fig. 5). The antibody responses peaked at days 42 (after dose 3) to 56 
and persisted to day 84, remaining high for all four genotypes. Interestingly, responses at day 42 were significantly 
stronger for genotype 1b compared to genotypes 1a, 2a and 3a. Furthermore, the durability of responses to day 
84 were also significantly stronger for genotype 1b compared to genotypes 1a, 2a and genotype 3a, which were all 
similar (Fig. 5).
Quadrivalent HCV VLP vaccine induces broad neutralizing antibody responses. Having shown 
that quadrivalent vaccine can produce strong antibody responses we then determined neutralizing antibody 
responses. Increasing dilutions of sera from the pigs immunized by the intradermal route were tested using cell 
culture derived Jc1 (genotype 2a) and genotype 3a HCVcc42. The sera from the vaccinated pigs inhibited Jc1 
HCVcc entry by 56–77% (mean 64% +/− SD 11%) at a dilution of 1:40, 50–67% (mean 55% +/− SD 12%) at a 
dilution of 1:120 and 42–50% (mean 46% +/− SD 4%) at a 1:400 dilution (Fig. 6A). Further dilution of sera to 
1:1200 resulted in little or no inhibition of HCVcc entry. Background levels of neutralization with pooled negative 
control pig serum were 10–16% (mean 12% +/− SD 8%), while the MAb24 positive control at all concentrations 
tested markedly inhibited HCVcc entry by 80–96% (mean 91% +/− SD 7%) (Fig. 6). Inhibition of entry was also 
observed with Gt3a, although the observed levels were somewhat lower across the three serum dilutions. Sera 
from the vaccinated pigs inhibited genotype 3a HCVcc entry by 36–64% (mean 48% +/− SD 15%) at a dilution 
of 1:40 but was less effective at higher dilutions, inhibiting entry by only 26–37% (mean 33% +/− SD 6%) at a 
dilution of 1:120 and 13–29% (mean 27% +/− SD 3%) at a 1:400 dilution (Fig. 6A).
HCV VLP cross neutralizing responses. Having demonstrated strong neutralizing antibody responses 
to the available HCVcc Gt2a and Gt3a genotypes we next determined the cross-neutralization efficacy of our 
quadrivalent vaccine. HCV VLP from the four different genotypes were labeled with FITC and neutralization 
of HCV entry into Huh7 cells was tested using immune sera from vaccinated pigs and compared against pooled 
Figure 2. Antibody responses elicited by immunization with quadrivalent vaccine. White Landrace pigs (n = 3/
group) were vaccinated with quadrivalent vaccine by intradermal microneedle injection or intramuscular 
injection. Antibody levels were determined by ELISA using heat-inactivated sera prepared from blood taken 
from all pigs at each of the indicated time points. Serum was diluted 1 in 500 in BSA5PBST and 50 µl of the 
diluted serum was added to VLP coated wells. The mean value and standard deviation is shown, this was 
calculated from the 3 pigs in each treatment group and is shown for each time point. P values in this, and other 
subsequent experiments were calculated using one-way ANOVA.
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non-immune pig sera (Fig. 6B). At the lowest dilution (1:80), sera from pigs immunized with HCV VLPs neu-
tralized genotype 1b VLPs by a mean of 55% (+/− SD 11%), compared with 61% (+/− SD 13%) for genotype 
1a, 75% (+/− SD 12%) for genotype 2a and 55% (+/− SD 18%) for genotype 3a. Significant levels of neutraliza-
tion against all four genotypes continued to be observed even at the higher serum dilutions (1:640 and 1:1280) 
Figure 3. Time course of VLP specific antibody responses following quadrivalent vaccination via intradermal 
microneedle injection. Anti-VLP antibody levels at days 21 (A), 42 (B), 56 (C), 70 (D) and 84 (E) were 
determined by ELISA using serially diluted heat-inactivated sera from each of the individual pigs. The mean 
value and standard deviation is shown for triplicate samples for each dilution. Geometric mean antibody titres 
peaked at day 42 and were maintained through to day 84 (F).
Figure 4. IgG1 and IgG2 responses generated after immunization with quadrivalent vaccine via intradermal 
microneedle injection. IgG1 and IgG2 antibody levels were determined by ELISA using heat-inactivated sera 
prepared from blood from all pigs at each time point. Serum was diluted 1 in 500 in BSA5PBST and 50 µl of 
the diluted serum was added to VLP coated wells. The mean value and standard deviation is shown, this was 
calculated from the 3 pigs in the group and is shown for each bleed.
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(Fig. 6B). As expected the pooled non-immune pig serum only neutralized HCV VLPs by 6% (+/− SD 5%) while 
anti-CD81 antibody significantly neutralized HCV VLPs by 84% (+/− SD 6%).
An important finding was that neutralizing antibody responses were strongest against genotype 2a in both the 
HCVcc and FITC-HCV VLP entry assays and responses were durable in all animals against all four serotypes out 
to day 84 (Supplementary figures 1–4).
HCV VLP Specific B-cell responses. We next assessed B-cell responses following vaccination with quad-
rivalent VLP by determining the number of specific memory B cells using an ELISpot assay with HCV VLPs as 
the detecting antigen at time points with available PBMCs. A strong response was observed on day 21 after the 
first dose of vaccine (mean 485 +/−SD 66)/million cells) compared to pre-vaccination (d0) (mean 206 +/− SD 
67)/million cells; p = 0.015) (Fig. 7A). The number of memory B cells increased significantly by day 42 (mean 
806 +/− SD 133)/million cells) and were maintained through to days 70 (mean 779 +/− SD 320)/million cells) 
and 84 (6 weeks after the last vaccine dose) (mean 846 +/− SD 257)/million cells) (Fig. 7A). The total number of 
memory B cells at days 42 and 84 following R848 stimulation, a bovine/porcine TLR9 ligand43, was 1419 +/− SD 
509/million cells and 2045 +/− SD 1163/million cells respectively (Fig. 7B). These results show that the quad-
rivalent VLP vaccine induces strong and durable HCV VLP-specific memory B cell responses. Plots for individual 
animals are included as a supplementary figure (Supplementary Fig. 5).
Vaccination induces HCV VLP-specific T-cell, Granzyme B and cytokine responses. Aside from 
the induction of broad neutralizing multi-genotypic antibody responses, an effective HCV vaccine needs to 
induce strong T cell responses. Therefore, we assessed the ability and durability of the quadrivalent VLP vaccine 
in induction of VLP-specific T cell responses in a large animal model. Unfortunately, the initial d21 sample time 
point could not be tested due to limited sample availability. The mean number of VLP-specific T cells secreting 
IFNγ by day 42 was 840 +/− SD 181 SFU (Fig. 8A). Although a modest decrease was observed by day 70 (mean 
759 SFU +/− SD 266, p = 0.0028) high VLP-specific T cell responses were maintained to day 84 post-vaccination 
(mean 998 SFU +/− SD 141/p = 0.0028) (Fig. 8A). Phytohemaglutinin (PHA) was used as positive control, pro-
ducing a strong IFNγ T cell response (mean 1279 SFU +/− SD 295).
To determine the magnitude and durability of the VLP-specific cytotoxic T cell responses in vivo we used a 
porcine granzyme B ELISA quantifying the amount of granzyme B present in the serum samples obtained from 
vaccinated pigs44. The mean concentration of granzyme B, calculated after subtracting the prebleed value, was 21 
pg/ml (+/−SD 3.2) at day 21 post vaccination (Fig. 8B). This increased to a maximum of 32 pg/ml (+/−SD 11) by 
day 42 and remained at 27 pg/ml (+/−SD 5.6) from d56 until the completion of the experiment at d84 (Fig. 8B). 
These results showed that the quadrivalent vaccine was able to produce durable cytotoxic T cell responses in vivo.
We also examined the cytokine profile in response to our vaccine using serum cytokine arrays (Fig. 8C). 
Vaccination did not appear induce inflammatory cytokine responses with the levels of IL-1a, 1b, 1ra, IL-6, TNFα 
or IFNγ below detection limits in the time points at which blood was available. In contrast, IL-12 levels were 
Figure 5. Genotype-specific antibody responses elicited by immunization with quadrivalent vaccine. Serum 
was diluted 1 in 500 in BSA5PBST and 50 µl of the diluted serum was added to genotype specific HCV VLP 
(Gt1a, Gt1b, Gt2a or Gt3a) coated wells. The mean value and standard deviation is shown, this was calculated 
from the 3 pigs at each time point.
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elevated from day 56 (p = 0.26) and IL-18 was transiently, but not significantly, elevated after the third dose 
of vaccine. These are interesting observations as IL-12 is important in initiating macrophage, NK and T cell 
responses that are important as a defence against viral infections. IL-18, together with IL12, is important in driv-
ing Th1 responses against viral pathogens. The vaccine did not induce an IL-10 response, an inhibitor of IL-12 
and T cell responses to viruses. IL-4, an important cytokine for Th2 responses and antibody production was also 
upregulated soon after vaccination (Fig. 8C).
Discussion
The elimination of chronic viral hepatitis has become an important goal of the WHO2. Although treatment with 
DAAs represents a major advance towards achieving this goal a number of modelling studies have indicated that 
DAAs alone will not be sufficient, however, if combined with an effective vaccine HCV elimination could poten-
tially be achieved45–49.
To this end, we have shown that our quadrivalent HCV VLP vaccine produces strong humoral and 
cell-mediated immune responses in a pre-clinical large animal model. Pigs are recognised as the closest animal 
model to humans, next to primates; as the porcine immune system more closely resembles humans than mice50. 
In addition, functional orthologs for cytokines involved in Th1, Th2 and Th17 responses and the corresponding 
cells have also been described in pigs51–53. In contrast to mice, young pigs also provide a large animal model with 
body weights that can be approximated to those of humans, an important consideration when trying to determine 
suitable vaccine doses. Hence, they serve as an ideal preclinical model to test the translational potential of our 
vaccine.
Our results show that the quadrivalent VLP vaccine administered intradermally without an adjuvant results in 
significantly stronger antibody responses than when given by intramuscular injection. The vaccine also produced 
long-lived B cell and genotype specific antibody responses and NAb response against genotypes 1a, 1b, 2a and 
3a HCV. The ability of the vaccine to produce these responses is analogous to hepatitis B vaccine, which can also 
produce long term protective antibody responses in the absence of adjuvant54,55. We know that the induction of 
NAb is associated in protection against HCV infection in chimpanzees, humanised uPa-SCID liver chimeric mice 
Figure 6. (A) Neutralizing antibody responses to quadrivalent VLP. Percentage HCV inhibition was 
determined by preincubating HCV infectious cell culture virus (HCVcc) genotype 2a or 3a with an equal 
amount of diluted immune serum from pigs inoculated by intradermal injection with quadrivalent VLP. Sera 
from the day 56 time point were used for all HCVcc neutralisation assays. Several serum dilutions (1:40, 1:140, 
1:400 and 1:1200) were tested. The concentrations (μg/ml) of the MAb24 used for each dilution series are as 
indicated. The negative control was pig IgG purified from pooled serum collected from pigs 10–12 at day 0. 
Individual animals are presented for each group, with the mean value being represented by the horizontal bar. 
(B) Cross-neutralising antibody responses to quadrivalent VLP. Percent neutralization was determined by pre-
incubating FITC labelled VLP (Gt1b, Gt1a, Gt2a or Gt3a) with increasing dilutions of day 56 serum (1:80 to 
1:2560) from pigs 10–12. Anti-CD81 and non- immunized pooled pig IgG were used as positive and negative 
controls respectively. The mean value and standard deviation is shown, this was calculated from pigs 10–12 and 
is shown for each dilution. Immune serum compared to negative pooled pig serum; *p < 0.001; **p < 0.01.
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and humans11,56 and so our results in pigs is an important finding as it reaffirms that our vaccine is able to produce 
such a response in a large animal.
The importance of NAb to HCV has been borne out in several studies showing that polyclonal and monoclo-
nal antibodies directed to conformational neutralizing epitopes protect human liver chimeric uPA/SCID mice 
Figure 7. Memory B cell responses following immunization with quadrivalent vaccine. (A) PBMCs were 
harvested on each of the days as indicated from the 3 individual pigs (10–12) and frequencies of HCV specific 
memory B cells were determined by B cell ELISpot assay. The y-axis shows memory B cells number/million 
PBMCs. The mean value and standard deviation is shown. This was calculated from the 3 pigs and is shown for 
each time point. (B) The total number of IgG memory B cells on days 42 and 84 following R848 stimulation (a 
TLR9 agonist).
Figure 8. T cell response following immunization with quadrivalent vaccine (A) IFNγ T cell responses. 
Frequencies of IFNγ secreting cells were determined by ELISpot assay. The y-axis shows spots/million 
PBMCs. The mean value and standard deviation is shown, this was calculated from the 3 pigs at each bleed. 
(B) Granzyme B responses. The concentration of granzyme B (pg/ml) present in pig sera at the indicated time 
points was determined with reference to a standard curve. The mean value and standard deviation is shown 
from the 3 pigs at each of the time points. (C) Cytokine profiles. Serum cytokine profiles were analysed at 
each time point using a Porcine Cytokine 13-Plex Discovery Assay. Yellow to red colour gradation represents 
increasing concentration of each cytokine (pg/ml).
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against challenge with HCV57. The most potent neutralizing human monoclonal antibodies (HuMAbs) recognise 
critical epitopes in the E1E2 heterodimers presented as complex tertiary or quaternary conformational structures 
on the surface of HCV58–65.
These potent HuMAbs predominantly recognize epitopes in domains B and D of the E2 protein, while 
HuMAbs binding to domain C are only weakly neutralizing58–60. Other potent neutralizing HuMAbs have also 
been described that target discontinuous epitopes outside domains B, C and D62,66. It appears that the develop-
ment of NAb may arise from public B cell clonotypes that recognize conserved epitopes and that these NAb pos-
sess a substantial breadth of neutralizing activity that may also include the early autologous transmitted/founder 
viruses67. Interestingly, broad NAb can also be detected up to 25 years after spontaneous clearance of HCV, sug-
gesting that the development of long-lived memory responses is possible68.
However, neutralization of all strains of HCV cannot be achieved with a single NAb as shown by recent studies 
reporting that several HuMAbs targeting different E2 domains can act synergistically to enhance neutralization 
of diverse strains of HCV compared to any individual NAb69,70. Several studies have approached NAb vaccines 
by designing recombinant antigens containing molecular scaffolds to present a limited number of E2 epitopes 
in a vaccine construct71 or developing truncated E2 proteins with deletion of variable regions to better expose 
conserved neutralization epitopes72,66. Whilst these vaccines are able to induce NAb production the recent studies 
reporting synergistic activity of different NAbs would argue that vaccination with full-length E1E2 as glycopro-
tein heterodimers or as VLPs presenting conformational epitopes may be advantageous since this vaccine is more 
likely to induce the production of combinations potent synergistically acting NAb to substantially enhance the 
breadth of neutralization against diverse strains of HCV69,70. This is analogous to the mechanism of neutralization 
described for flaviviruses like dengue73,74 and has important implications for vaccine design as an effective HCV 
vaccine will need to deliver multiple conformational epitopes that will result in the production of NAb with broad 
binding specificities70. HCV VLPs have the ability to achieve this goal and are therefore an attractive vaccine 
candidate for HCV20,21,25,26,32,33.
We have previously shown that our quadrivalent vaccine produces strong T cell and granzyme B responses in 
mice35,36,25,34. In this study we have shown a similar response in pigs, together with a favorable cytokine profile. 
The importance of both CD4+ and CD8+ T cell responses in clearance of and protection against HCV has been 
borne out by numerous studies17,22,24,75–78. In humans, strong and broad HCV core specific T cell responses are 
important in spontaneous viral clearance22–24. In contrast to persistent infection, spontaneous resolution of HCV 
infection in humans has been temporally linked to the appearance of strong, long-lived, polyfunctional CD4+ 
and CD8+ T cell responses that are directed against multiple HCV antigens and particularly the core protein79. 
Furthermore, we and others have shown that the potency of cytolytic T cell responses are crucial for protection 
against HCV19,77. In chimpanzees, CD4+ and CD8+ T cell depletion results in HCV persistence after viral chal-
lenge75 and rechallenge with homologous virus after spontaneous clearance results in the rapid re-expansion of 
HCV-specific CD8+ T cells in both blood and the liver and clearance of viraemia76. Our quadrivalent vaccine will 
deliver antigens capable of inducing HCV specific T cell responses in a large animal.
The advantage of presenting multiple HCV antigens, as a quadrivalent HCV VLP vaccine does, is also high-
lighted by a number of studies. The co-administration of a mixture of recombinant genotype 1b HCV core, E1, 
E2 proteins has been shown to induce strong HCV core specific T cell responses in vaccinated mice and African 
green monkeys12. Furthermore, vaccinated mice were able to control viremia after challenge with vaccinia virus 
expressing HCV structural proteins (vvRE)12. Recombinant human adenovirus 6 (Ad6) and chimpanzee ade-
novirus 3 (ChAd3) vaccines containing HCV non-structural genes have also been shown to produce long-lived 
polyfunctional central and effector memory CD4+ and CD8+ T cell responses against multiple homologous and 
heterologous (genotype 1a and 3a) HCV proteins16. In humans, a heterologous prime-boost vaccination strategy 
with ChAd3 and MVA vectors encoding the non-structural proteins of HCV genotype 1b produced high levels 
of polyfunctional CD8+ and CD4+ HCV-specific T cells targeting multiple homologous and heterologous HCV 
antigens together with sustained memory and effector T cell populations17. The limitation with these vaccines, 
however, is that unlike HCV VLPs, they do not produce NAb responses, a critical part of protection against HCV. 
Finally, it has also been shown that T cell responses of individuals with chronic hepatitis C infection are likely to 
be genotype specific with limited cross reactivity80,81. This would argue that, as with NAb, an effective vaccine will 
need to contain T cell antigens of more than a single genotype.
Our study also demonstrated that the administration of the quadrivalent vaccine by the intradermal route 
using a microneedle device resulted in stronger antibody response than the intramuscular route. The inocula-
tion of vaccines using microneedle devices or intradermal injection has been shown to produce strong immune 
responses82–85. The delivery of vaccines to the skin using intradermal injection and microneedle devices presents 
antigens directly to unique populations of resident cutaneous antigen presenting cells (APCs), ensures a more 
accurate, effective and reproducible delivery of vaccine to the dermis and has an antigen sparing benefit85. The 
delivery of hepatitis B vaccine by intradermal injection for example has been shown to result in higher serocon-
version rates and antibody titres than intramuscular inoculation86. Also, intradermal inoculation of hepatitis B 
vaccine results in higher seroconversion rates and antibody titres than intramuscular inoculation in patients with 
chronic renal failure87 and chronic liver disease88. Microneedles also allow for the delivery of multiple antigens89. 
A more effective production of protective influenza antibody responses has been reported following intradermal 
microneedle inoculation of vaccine85. Immunization of mice with influenza H5 VLPs by microneedle device pro-
duces durable humoral and cellular immune responses, including IgG1 and IgG2a antibody isotypes, consistent 
with both Th1 and Th2 responses90. These responses also translated to better protection against challenge with 
H5N1 avian influenza compared to intramuscular vaccination91. Vaccination of pigs with the quadrivalent vac-
cine also resulted in both IgG1 and 2 antibody responses. Similarly, intradermal influenza vaccine has also been 
shown to produce strong seroprotective antibody responses in humans92. Microneedle devices have been devel-
oped for the effective delivery of live viral vaccines like measles93. These investigators reported the development 
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of long-lasting measles NAb responses in macaques following intradermal inoculation with a microneedle. These 
findings are similar to the responses we observed in pigs given the quadrivalent vaccine by intradermal route with 
a microneedle.
In conclusion, a vaccine to prevent persistent infection with HCV is not only an achievable goal but one that 
would also make a significant addition to the armamentarium required to eliminate hepatitis C globally. Our 
quadrivalent HCV VLP vaccine holds promise as it is able to produce long-lived broad genotype specific and 
NAb responses in a large animal model together with strong T cell and granzyme B responses and a normal Th1 
and Th2 cytokine response. Based on these findings and our previous report demonstrating that critical epitopes 
for neutralization are expressed on the particles, our quadrivalent HCV VLP vaccine fulfills the requirements 
expected of an effective HCV vaccine candidate.
Methods
production of HCV VLps. Construction of recombinant adeno-encoding HCV structural proteins core E1 
and E2 and the large-scale production, purification and characterisation of the quadrivalent genotype 1a, 1b, 2a, 
and 3a HCV VLP vaccine used in this study has been reported previously25,27,34. MAb24 is a murine NAb that 
recognizes a linear epitope in the E2661 protein that lacks the HVR1, HVR2 and igVR regions72.
Protocol for immunization of pigs. White Landrace pigs were obtained from the University of Adelaide 
Roseworthy Campus and were housed at the Large Animal Research Facility, South Australian Health and 
Medical Research Institute. Vaccination studies were performed in two groups of three 6-week old outbred White 
Landrace pigs comparing intradermal (ID) and intramuscular (IM) routes of inoculation (Fig. 1). To ensure 
reproducible intradermal delivery of quadrivalent VLP, the immunisations were performed using a microneedle 
device (FluGen Inc, Wisconsin, USA) which delivered the VLP in a volume of 250 μl of saline. For group 1, White 
Landrace pigs were vaccinated with the quadrivalent vaccine by intradermal microneedle injection while group 2 
were vaccinated by intramuscular injection, both without adjuvant. Pigs in each group received three doses of 75 
µgs per HCV VLP genotype (total of 300 µgs of HCV VLPs) vaccine at 21-day intervals in the upper inner front 
leg. The pigs were bled aseptically through the jugular vein and blood processed for serum and PBMCs at baseline 
(d0), before each booster (days 21 and 42) and again on days 56, 70 and 84.
The University of Adelaide and the South Australia Pathology Animal Ethics Committees approved all exper-
imental protocols (Animal Ethics Committee approval number M-2012-177). All procedures adhered to the 
Australian code for the care and use of animals for scientific purposes 8th edition 2013, Australian Government, 
National Health and Medical Research Council.
preparation of porcine pBMCs. PBMC were isolated from peripheral blood using Lymphoprep (StemCell 
Technologies) as per manufacturer’s instructions. Briefly, blood was diluted with an equal amount of Dulbecco’s 
Phosphate-Buffered Saline with 2% Fetal Bovine Serum (PBS + 2% FBS) and layered on top of Lymphoprep, fol-
lowed by centrifugation at 800 × g for 20 minutes at room temperature (15–25 °C) without the brake applied. The 
PBMC interface was carefully removed by pipetting and washed with PBS + 2% FBS by centrifugation at 300  ×  g 
for 10 min. Cell number and viability were determined using a Countess Automated Cell Counter (Invitrogen). 
PBMC were cryopreserved in liquid nitrogen in 90% FCS containing 10% dimethyl sulfoxide (DMSO; Sigma 
Aldrich) and stored until required for downstream analyses.
Enzyme-linked immunosorbent assay. Anti-HCV VLP antibody titres were determined by ELISA as 
previously described25,36. In brief, for VLP-specific antibody responses, flat bottom 96-well polyvinyl plates were 
coated with purified quadrivalent VLPs (5 µg/ml) in carbonate coating buffer (100 mM Na2CO3, and NaHCO3, 
pH 9.6) overnight at 4 °C. The plates were then blocked with 100 µl of BSA (10 mg/ml) in PBS and incubated for 
1 hour at 37 °C before washing four times with PBST (PBS containing 0.05%v/v Tween-20). For titration of anti-
body response heat inactivated serum was serially diluted 0.5-log10 in BSA (5 mg/ml) in PBST and incubated for 
1 hour at 37 °C. To determine the strength of antibody responses at different time points, pig serum was diluted 
1 in 500 in BSA5PBST and 50 µl of the diluted serum was added to the wells of a VLP coated plate. Identical 
serum dilutions and conditions were also used for determination of genotype-specific antibody and IgG1 and 
2 responses. Absorbance values were determined on a Labsystems Multiskan Multisoft plate reader at 450 nm. 
Titres of antibody are expressed as the reciprocal of the highest dilution of serum required to achieve an optical 
density of 0.2.25,42.
HCV Neutralization assay. Neutralization assays against HCV infectious cell culture system (HCVcc) were 
performed by mixing HCVcc virus with an equal volume of serially diluted immune serum, using methods as 
previously described36,94. Sera from the day 56 time point were used for all HCVcc neutralization assays. Each 
experiment was performed in triplicate. The virus/serum mixture was incubated for 1 h at 37 °C before addition 
to Huh7.5 cells that were seeded 24 h earlier at 30,000 cells/well in 48 well plates for 4 h. Cells were washed at 
least 4 times and replenished with fresh DMF10NEAA and incubated for a further 48–72 h. Luciferase activity 
was measured in clarified lysates using Renilla luciferase substrate (Promega) and a FLUOstar Optima microplate 
reader fitted with luminescence optics (BMG Life Technologies, Germany). The neutralization titre was calculated 
from 6-point dilution curves as the reciprocal dilution of serum to reduce luciferase activity by 50% (ID50). The 
data shown is the mean from at least two independent experiments. MAb24, used as a positive control for inhibi-
tion of HCVcc entry, is a murine NAb that recognizes a linear epitope in the modified recombinant E2661 protein 
that lacks the HVR1, HVR2 and igVR regions. The MAb24 antibody is produced using a Miniperm bioreactor, 
with a final concentration of the antibody of 150 µg/ml. The antibody is diluted 1 in 8 (18 µg/ml) and then used in 
a series of 0.5 log10 dilutions72. Pig IgG purified from pooled non-immune serum was used as the negative control.
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The inhibition of entry of HCV VLPs into Huh7 cells by immune pig sera was determined by flow cytometry 
(FACS Canto II, BD Bioscience) using FITC labelled HCV VLP and analysed using the WEASEL 2.0 software 
package (Walter and Eliza Hall Institute, Melbourne, Australia) as described previously34. Sera that demonstrated 
a decrease in specific cellular binding of 50% or more were considered neutralizing. As a positive control, inhibi-
tion of entry of FITC-HCV VLPs into Huh7 cells was also determined using anti-CD81 antibody (Abcam, USA).
HCV specific B Cell responses. For the detection of specific antibody secreting cells by ELISpot, Pig 
PBMCs were stimulated with R848, a TLR9 agonist43 (Invivogen, USA) for five days, cultured on ELISPOT plates 
and developed using a standardized Porcine IgG ELISpotBASIC (HRP) ELISpot kit (Mabtech Inc., Cincinnati, OH, 
USA). Briefly, polyvinylidene fluoride (PVDF) membrane-lined 96-well plates (Millipore, Ireland) were coated 
with 100 µl of PBS containing quadrivalent VLPs (4 µg/well or 40 µg/ml) as previously described25,36,95 or 15 µg/
ml of anti-Pig IgG (monoclonal antibody MT421). The plates were incubated overnight at 4 °C, washed with PBS, 
and blocked using complete R10 medium for 30 minutes. Stimulated PBMCs were then added to the ELISPOT 
wells and cultured in the plates overnight at 37 °C with 5% CO2. After 24 hours, wells were washed and biotiny-
lated anti-IgG (monoclonal antibody MT424) antibody was added for 2 hours at room temperature. This was 
followed by streptavidin-conjugated horse-radish peroxidase (both from Mabtech, USA) and incubating for 1 
hour at room temperature and detected with TMB substrate. Individual spots were then scanned, counted and 
analysed on an AID EliSpot Reader (Strassberg, Germany).
Analysis of IFN-γ-secreting Cells. ELISpot assays were carried out using the IFN-γ ELISpotBASIC (HRP) 
kit (Mabtech, USA) with PVDF membrane-lined 96-well plates (Millipore, Ireland) as described previously36. 
Wells were precoated with anti-IFN-γ capture monoclonal antibody pIFNγ-I at 10 µg/ml. Following coating, 
plates were then blocked with RF 10 medium. PBMCs stimulated for 5 days with 20 µg total VLPs per well were 
harvested, washed and serial dilutions commencing at 1 × 105 cells/ml added to the wells. Forty-eight hours 
later, plates were washed with PBS and biotinylated anti-IFN-γ capture antibody (P2C11-biotin) was added and 
incubated for 2 hours at room temperature in a humidified atmosphere. Plates were then washed and streptavidin 
conjugated horse-radish peroxidase (Mabtech, USA) was added and incubated for one hour. Spots representative 
of IFN-γ-producing cells were developed by the addition of TMB.
Analysis of granzyme B-secreting cells. For the detection of Granzyme B-secreting cells, a Porcine 
Granzyme B (GZMB) ELISA Kit (MyBioSource, USA) was used according to the manufacturer’s instructions. 
ELISA strip wells, precoated with Porcine GZMB monoclonal antibody were used for test samples and standards. 
Porcine GZMB standards were set up to give final concentrations of 1000, 500, 250, 125, 62.5, 31.2,15.6 pg/ml. 
Porcine sera was added in triplicates to the wells, followed by biotinylated polyclonal porcine GZMB antibody 
(1:100) and detected with the Colour Reagent provided by the manufacturer. Absorbance values were determined 
on a Labsystems Multiskan Multisoft plate reader at 450 nm and a standard curve was used to quantify the GZMB 
(pg/ml).
Cytokine arrays. Serum cytokine profiles following vaccination were analysed using a Porcine Cytokine 
13-Plex Discovery Assay (Eve Technologies, Calgary, Canada).
statistical analysis. Statistical analysis was performed using the Prism 5.0 software (GraphPad)36. In all 
cases the mean ± standard deviation of the mean (SD) is shown unless otherwise stated. P values for statistical 
analysis were calculated using one-way ANOVA with Tukey’s multiple comparison test. Differences were consid-
ered statistically significant when p values were less than 0.05 (p < 0.05) with a 95% confidence level.
References
 1. Sacks-Davis, R. et al. High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: 
a prospective cohort study. PLoS One 8, e80216, https://doi.org/10.1371/journal.pone.0080216 (2013).
 2. World Health Organization. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Available at, http://apps.who.
int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1., Accessed April, 2018. (2017).
 3. Liang, T. J. & Ward, J. W. Hepatitis C in Injection-Drug Users - A Hidden Danger of the Opioid Epidemic. N Engl J Med 378, 
1169–1171, https://doi.org/10.1056/NEJMp1716871 (2018).
 4. Zibbell, J. E. et al. Increases in hepatitis C virus infection related to injection drug use among persons aged </= 30 years - Kentucky, 
Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep 64, 453–458 (2015).
 5. Division of Viral Hepatitis, N. C. f. H. A., Viral Hepatitis, STD, and TB Prevention. Progress toward viral hepatitis elimination in the 
United States, 2017).
 6. Prevention, C. f. D. C. a. Viral Hepatitis Surveillance—United States, 2015. Atlanta: US Department of Health and Human Services, 
Centers for Disease Control and Prevention; Available at, https://www.cdc.gov/hepatitis/statistics/2015surveillance/
pdfs/2015HepSurveillanceRpt.pdf (2015).
 7. Control., E. C. f. D. P. a. Hepatitis C. In: ECDC. Annual epidemiological report for 2015. Stockholm: ECDC; 2017., Available from, 
http://ecdc.europa.eu/en/healthtopics/hepatitisb/Pages/Annualepidemiologicalreport2016.aspx.
 8. Institute, T. K. Monitoring hepatitis C treatment uptake in Australia (Issue 6). Sydney, Australia: The Kirby Institute, UNSW Sydney; 
February 2017., http://kirby.unsw.edu.au/research-programs/vhcrp-newsletters.
 9. Hepatitis C Mapping Project: Estimates of geographic diversity in chronic hepatitis C prevalence, diagnosis, monitoring and 
treatment - National Report 2016, https://www.ashm.org.au/products/product/HepC-Mapping-Report-2016 (2017).
 10. Osburn, W. O. et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. 
Gastroenterology 138, 315–324, https://doi.org/10.1053/j.gastro.2009.09.017 (2010).
 11. Osburn, W. O. et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody 
responses. Hepatology 59, 2140–2151, https://doi.org/10.1002/hep.27013 (2014).
 12. Martinez-Donato, G. et al. Neutralizing antibodies and broad, functional T cell immune response following immunization with 
hepatitis C virus proteins-based vaccine formulation. Vaccine 32, 1720–1726, https://doi.org/10.1016/j.vaccine.2014.01.046 (2014).
1 1Scientific RepoRts |          (2019) 9:9251  | https://doi.org/10.1038/s41598-019-45461-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
 13. Huret, C. et al. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and 
neutralizing immune responses in mice. Vaccine 31, 1540–1547, https://doi.org/10.1016/j.vaccine.2012.05.025 (2013).
 14. Folgori, A. et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 
12, 190–197, https://doi.org/10.1038/nm1353 (2006).
 15. Mikkelsen, M., Holst, P. J., Bukh, J., Thomsen, A. R. & Christensen, J. P. Enhanced and sustained CD8+ T cell responses with an 
adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J 
Immunol 186, 2355–2364, https://doi.org/10.4049/jimmunol.1001877 (2011).
 16. Barnes, E. et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4, 
115ra111, https://doi.org/10.1126/scitranslmed.3003155 (2012).
 17. Swadling, L. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains 
functional HCV-specific T cell memory. Sci Transl Med 6, 261ra153, https://doi.org/10.1126/scitranslmed.3009185 (2014).
 18. Kumar, A. et al. Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus 
boost strategy. Vaccine 34, 1115–1125, https://doi.org/10.1016/j.vaccine.2015.11.061 (2016).
 19. Wijesundara, D. K. et al. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-
Vaccinated Mice. J Virol 92, https://doi.org/10.1128/JVI.02133-17 (2018).
 20. Torresi, J. The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine. Front Microbiol 8, 2163, https://doi.org/10.3389/
fmicb.2017.02163 (2017).
 21. Masavuli, M. G., Wijesundara, D. K., Torresi, J., Gowans, E. J. & Grubor-Bauk, B. Preclinical Development and Production of Virus-
Like Particles As Vaccine Candidates for Hepatitis C. Front Microbiol 8, 2413, https://doi.org/10.3389/fmicb.2017.02413 (2017).
 22. Smyk-Pearson, S. et al. Differential antigenic hierarchy associated with spontaneous Recovery from hepatitis C virus infection: 
implications for vaccine design. J Infectious Diseases 194, 454–463 (2006).
 23. Neumann-Haefelin, C. et al. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in 
chronic hepatitis C virus infection. Hepatology 47, 1824–1836, https://doi.org/10.1002/hep.22242 (2008).
 24. Schulze Zur Wiesch, J. et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, 
but rapidly disappear from human blood with viral persistence. The Journal of experimental medicine 209, 61–75, https://doi.
org/10.1084/jem.20100388 (2012).
 25. Chua, B. Y. et al. Hepatitis C VLPs Delivered to Dendritic Cells by a TLR2 Targeting Lipopeptide Results in Enhanced Antibody and 
Cell-Mediated Responses. PLoS One 7, e47492, https://doi.org/10.1371/journal.pone.0047492 (2012).
 26. Beaumont, E., Patient, R., Hourioux, C., Dimier-Poisson, I. & Roingeard, P. Chimeric hepatitis B virus/hepatitis C virus envelope 
proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology 57, 1303–1313, 
https://doi.org/10.1002/hep.26132 (2013).
 27. Earnest-Silveira, L. et al. Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine. 
Journal of virological methods 236, 87–92, https://doi.org/10.1016/j.jviromet.2016.06.012 (2016).
 28. Baumert, T. F., Ito, S., Wong, D. T. & Liang, T. J. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. 
J. Virol. 72, 3827–3836 (1998).
 29. Baumert, T. F. et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 117, 
1397–1407 (1999).
 30. Steinmann, D. et al. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic 
hepatitis C. J Virol 78, 9030–9040 (2004).
 31. Murata, K. et al. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia 
infection. Proc. Natl. Acad. Sci. USA 100, 6753–6758 (2003).
 32. Garrone, P. et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing 
antibodies in macaques. Sci Transl Med 3, 94ra71, https://doi.org/10.1126/scitranslmed.3002330 (2011).
 33. Elmowalid, G. A. et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in 
chimpanzees. Proc Natl Acad Sci USA 104, 8427–8432 (2007).
 34. Earnest-Silveira, L. et al. Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell 
line. The Journal of General Virology 97, 1865–1876, https://doi.org/10.1099/jgv.0.000493 (2016).
 35. Christiansen, D. et al. Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like 
Receptor 2 Agonists. Viral Immunol, https://doi.org/10.1089/vim.2017.0182 (2018).
 36. Christiansen, D. et al. Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. 
Sci Rep 8, 6483, https://doi.org/10.1038/s41598-018-24762-9 (2018).
 37. Mehlhop, E. et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-
specific manner. Cell Host Microbe 2, 417–426, https://doi.org/10.1016/j.chom.2007.09.015 (2007).
 38. Rodrigo, W. W. et al. Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology 
394, 175–182, https://doi.org/10.1016/j.virol.2009.09.024 (2009).
 39. Hofmeister, Y. et al. Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus. J Virol 85, 
1896–1899, https://doi.org/10.1128/JVI.02155-10 (2011).
 40. Cao, R. Y. et al. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of 
infection. PLoS One 8, e64024, https://doi.org/10.1371/journal.pone.0064024 (2013).
 41. Irani, V. et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies 
against infectious diseases. Mol Immunol 67, 171–182, https://doi.org/10.1016/j.molimm.2015.03.255 (2015).
 42. Vietheer, P. T. et al. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea 
pigs. Hepatology 65, 1117–1131, https://doi.org/10.1002/hep.28989 (2017).
 43. Braun, R. O., Python, S. & Summerfield, A. Porcine B Cell Subset Responses to Toll-like Receptor Ligands. Front Immunol 8, 1044, 
https://doi.org/10.3389/fimmu.2017.01044 (2017).
 44. Ewen, C. L., Rong, J., Kokaji, A. I., Bleackley, R. C. & Kane, K. P. Evaluating antigen-specific cytotoxic T lymphocyte responses by a 
novel mouse granzyme B ELISPOT assay. J Immunol Methods 308, 156–166, https://doi.org/10.1016/j.jim.2005.10.009 (2006).
 45. Sievert, W. et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease 
and costs in Australia. Journal of Gastroenterology and Hepatology 29(Suppl 1), 1–9, https://doi.org/10.1111/jgh.12677 (2014).
 46. Martin, N. K. et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the 
age of direct-acting antivirals. Hepatology 58, 1598–1609, https://doi.org/10.1002/hep.26431 (2013).
 47. Hellard, M. E. et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, 
Australia. The Medical journal of Australia 196, 638–641 (2012).
 48. Hahn, J. A. et al. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics 1, 47–57, 
https://doi.org/10.1016/j.epidem.2008.10.002 (2009).
 49. Scott, N. et al. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med 
13, 198, https://doi.org/10.1186/s12916-015-0440-2 (2015).
 50. Meurens, F., Summerfield, A., Nauwynck, H., Saif, L. & Gerdts, V. The pig: a model for human infectious diseases. Trends Microbiol 
20, 50–57, https://doi.org/10.1016/j.tim.2011.11.002 (2012).
 51. Kaser, T., Gerner, W. & Saalmuller, A. Porcine regulatory T cells: mechanisms and T-cell targets of suppression. Dev Comp Immunol 
35, 1166–1172, https://doi.org/10.1016/j.dci.2011.04.006 (2011).
1 2Scientific RepoRts |          (2019) 9:9251  | https://doi.org/10.1038/s41598-019-45461-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
 52. Kiros, T. G., van Kessel, J., Babiuk, L. A. & Gerdts, V. Induction, regulation and physiological role of IL-17 secreting helper T-cells 
isolated from PBMC, thymus, and lung lymphocytes of young pigs. Vet Immunol Immunopathol 144, 448–454, https://doi.
org/10.1016/j.vetimm.2011.08.021 (2011).
 53. Murtaugh, M. P., Johnson, C. R., Xiao, Z., Scamurra, R. W. & Zhou, Y. Species specialization in cytokine biology: is interleukin-4 
central to the T(H)1-T(H)2 paradigm in swine? Dev Comp Immunol 33, 344–352, https://doi.org/10.1016/j.dci.2008.06.014 (2009).
 54. Bruce, M. G. et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to 
a Booster Dose. J Infect Dis 214, 16–22, https://doi.org/10.1093/infdis/jiv748 (2016).
 55. Zhu, C. L. et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. 
Vaccine 29, 7835–7841, https://doi.org/10.1016/j.vaccine.2011.07.098 (2011).
 56. Dorner, M. et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 474, 208–211, https://doi.
org/10.1038/nature10168 (2011).
 57. Meuleman, P. et al. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. 
Hepatology 53, 755–762, https://doi.org/10.1002/hep.24171 (2011).
 58. Keck, Z. et al. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct propertires 
and biological functions. J. Virol. 78, 9224–9232 (2004).
 59. Keck, Z. Y. et al. Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. Journal of Virology 79, 
13199–13208, https://doi.org/10.1128/JVI.79.21.13199-13208.2005 (2005).
 60. Keck, Z. Y. et al. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human 
monoclonal antibodies. Journal of Virology 82, 6061–6066, https://doi.org/10.1128/JVI.02475-07 (2008).
 61. Law, M. et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14, 25–27 (2008).
 62. Giang, E. et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proceedings of the 
National Academy of Sciences of the United States of America 109, 6205–6210, https://doi.org/10.1073/pnas.1114927109 (2012).
 63. Keck, Z. et al. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino 
terminus of hepatitis C virus E2 glycoprotein. Journal of Virology 87, 37–51, https://doi.org/10.1128/JVI.01941-12 (2013).
 64. Keck, Z. Y. et al. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus 
infection in mice. Hepatology 64, 1922–1933, https://doi.org/10.1002/hep.28850 (2016).
 65. Fauvelle, C. et al. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines 15, 
1535–1544, https://doi.org/10.1080/14760584.2016.1194759 (2016).
 66. Kong, L. et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342, 1090–1094, https://doi.org/10.1126/
science.1243876 (2013).
 67. Bailey, J. R. et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight 2, e92872, 
https://doi.org/10.1172/jci.insight.92872 (2017).
 68. Merat, S. J. et al. Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance. PLoS 
One 11, e0165047, https://doi.org/10.1371/journal.pone.0165047 (2016).
 69. Carlsen, T. H. et al. Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV 
genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology 60, 1551–1562, https://doi.org/10.1002/hep.27298 (2014).
 70. Mankowski, M. C. et al. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. 
Proc Natl Acad Sci USA 115, E82–E91, https://doi.org/10.1073/pnas.1718441115 (2018).
 71. Pierce, B. G. et al. Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved 
Epitope. J Virol 91, https://doi.org/10.1128/JVI.01032-17 (2017).
 72. Alhammad, Y. et al. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences 
Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region. J Virol 89, 
12245–12261, https://doi.org/10.1128/JVI.02070-15 (2015).
 73. Pierson, T. C. & Diamond, M. S. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol 
Med 10, e12, https://doi.org/10.1017/S1462399408000665 (2008).
 74. Dowd, K. A. & Pierson, T. C. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411, 306–315, https://
doi.org/10.1016/j.virol.2010.12.020 (2011).
 75. Grakoui, A. et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302, 659–662 (2003).
 76. Ramalingam, R. K. et al. Kinetic analysis by real-time PCR of hepatitis C virus (HCV)-specific T cells in peripheral blood and liver 
after challenge with HCV. J Virol 82, 10487–10492, https://doi.org/10.1128/JVI.00588-08 (2008).
 77. Bharadwaj, M. et al. TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus. Immunology and Cell Biology 87, 
464–472 (2009).
 78. Grubor-Bauk, B. et al. Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice 
and pigs. Gene Ther 23, 26–37, https://doi.org/10.1038/gt.2015.86 (2016).
 79. Lechner, F. et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191, 1499–1512 
(2000).
 80. Lucas, M. et al. Evidence of CD4(+) T cell-mediated immune pressure on the Hepatitis C virus genome. Sci Rep 8, 7224, https://doi.
org/10.1038/s41598-018-25559-6 (2018).
 81. von Delft, A. et al. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with 
implications for vaccine design. Gut 65, 112–123, https://doi.org/10.1136/gutjnl-2014-308724 (2016).
 82. Li, N., Wang, N., Wang, X., Zhen, Y. & Wang, T. Microneedle arrays delivery of the conventional vaccines based on nonvirulent 
viruses. Drug Deliv 23, 3234–3247, https://doi.org/10.3109/10717544.2016.1165311 (2016).
 83. Marshall, S., Sahm, L. J. & Moore, A. C. The success of microneedle-mediated vaccine delivery into skin. Hum Vaccin Immunother 
12, 2975–2983, https://doi.org/10.1080/21645515.2016.1171440 (2016).
 84. Al-Zahrani, S. et al. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy. Expert Opin 
Drug Deliv 9, 541–550, https://doi.org/10.1517/17425247.2012.676038 (2012).
 85. Prausnitz, M. R., Mikszta, J. A., Cormier, M. & Andrianov, A. K. Microneedle-based vaccines. Current topics in microbiology and 
immunology 333, 369–393, https://doi.org/10.1007/978-3-540-92165-3_18 (2009).
 86. Henderson, E. A. et al. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of 
healthcare workers. Infect Control Hosp Epidemiol 21, 264–269, https://doi.org/10.1086/501756 (2000).
 87. Yousaf, F., Gandham, S., Galler, M., Spinowitz, B. & Charytan, C. Systematic review of the efficacy and safety of intradermal versus 
intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series. Ren Fail 37, 
1080–1088 (2015).
 88. Dhillon, S. et al. Efficacy of high-dose intra-dermal hepatitis B virus vaccine in previous vaccination non-responders with chronic 
liver disease. Dig Dis Sci 57, 215–220, https://doi.org/10.1007/s10620-011-1996-0 (2012).
 89. Matsuo, K. et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, 
and influenza. J Control Release 160, 495–501, https://doi.org/10.1016/j.jconrel.2012.04.001 (2012).
 90. Song, J. M. et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses 
in mice. Clin Vaccine Immunol 17, 1381–1389, https://doi.org/10.1128/CVI.00100-10 (2010).
 91. Song, J. M. et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin 
using microneedles. Antiviral research 88, 244–247, https://doi.org/10.1016/j.antiviral.2010.09.001 (2010).
13Scientific RepoRts |          (2019) 9:9251  | https://doi.org/10.1038/s41598-019-45461-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
 92. Bragazzi, N. L., Orsi, A., Ansaldi, F., Gasparini, R. & Icardi, G. Fluzone(R) intra-dermal (Intanza(R)/Istivac(R) Intra-dermal): An 
updated overview. Hum Vaccin Immunother 12, 2616–2627, https://doi.org/10.1080/21645515.2016.1187343 (2016).
 93. Edens, C., Collins, M. L., Goodson, J. L., Rota, P. A. & Prausnitz, M. R. A microneedle patch containing measles vaccine is 
immunogenic in non-human primates. Vaccine 33, 4712–4718, https://doi.org/10.1016/j.vaccine.2015.02.074 (2015).
 94. Gottwein, J. M. et al. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 
(NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. J Virol 85, 8913–8928, https://doi.org/10.1128/
JVI.00049-11 (2011).
 95. Chin, R. et al. Impaired dendritic cell maturation in response to pandemic H1N109 influenza virus. Journal of clinical virology, 
https://doi.org/10.1016/j.jcv.2012.11.009 (2012).
Acknowledgements
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia, grant 
numbers 1060436 and 1126379. JT was supported by an NHMRC Practitioner Fellowship, number 106043.
Author Contributions
D.C., L.E.S. and J.T. designed this study and wrote the manuscript. D.C. and L.E.S., I.B., B.G.-B., D.W. performed 
the experiments. H.E.D., E.J.G., P.A.R. and E.V., provided materials, intellectual guidance and contributed to data 
analysis. All authors read and provided input on the manuscript, and approved the final version.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-45461-z.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
